Paragangliomas (PGLs) are catecholamine-secreting neoplasms of chromaffin cells and represent a rare but curable cause of secondary hypertension. Surgery is the treatment of choice for symptomatic PGLs. A small (7 mm) extra-adrenal PGL was diagnosed in the right retroperitoneal space in a 19-year-old patient affected by symptomatic hypertension unresponsive to medical treatment. Indication to percutaneous radiofrequency ablation (RFA) was given by a multidisciplinary team on the basis of the size of the nodule, the surgical risks, the young age of the patient, and his wish to reduce as much as possible the post-interventional rehabilitation. To our knowledge, the use of percutaneous RFA in the treatment of retroperitoneal extra-adrenal primary paragangliomas has never been described. We describe its feasibility and the patient’s clinical outcome.
Immediate Clinical Success After Percutaneous Ablation of Extra-adrenal Paraganglioma / A.M. Ierardi, P. Biondetti, G. Ferrante, S. Carugo, G. Carrafiello. - In: CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY. - ISSN 0174-1551. - 41:11(2018 Nov), pp. 1803-1806.
Immediate Clinical Success After Percutaneous Ablation of Extra-adrenal Paraganglioma
P. BiondettiSecondo
;G. Ferrante;S. CarugoPenultimo
;G. Carrafiello
Ultimo
2018
Abstract
Paragangliomas (PGLs) are catecholamine-secreting neoplasms of chromaffin cells and represent a rare but curable cause of secondary hypertension. Surgery is the treatment of choice for symptomatic PGLs. A small (7 mm) extra-adrenal PGL was diagnosed in the right retroperitoneal space in a 19-year-old patient affected by symptomatic hypertension unresponsive to medical treatment. Indication to percutaneous radiofrequency ablation (RFA) was given by a multidisciplinary team on the basis of the size of the nodule, the surgical risks, the young age of the patient, and his wish to reduce as much as possible the post-interventional rehabilitation. To our knowledge, the use of percutaneous RFA in the treatment of retroperitoneal extra-adrenal primary paragangliomas has never been described. We describe its feasibility and the patient’s clinical outcome.File | Dimensione | Formato | |
---|---|---|---|
Ierardi2018_Article_ImmediateClinicalSuccessAfterP.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
722.62 kB
Formato
Adobe PDF
|
722.62 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.